Reuters logo
CORRECTED-FDA studying deaths of two patients on Lilly's long-acting Zyprexa
June 18, 2013 / 2:27 PM / 4 years ago

CORRECTED-FDA studying deaths of two patients on Lilly's long-acting Zyprexa

(Corrects headline to FDA studying, rather than Lilly)

June 18 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it was investigating deaths of two patients who died following injections with Eli Lilly and Co’s long-acting treatment for schizophrenia, called Zyprexa Relprevv.

The agency said the patients died 3 to 4 days after receiving an appropriate dose of the medicine.

Reporting by Ransdell Pierson; Editing by Gerald E. McCormick

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below